Evaluation and management of measurable residual disease in acute lymphoblastic leukemia

With standard chemotherapy regimens for adults with acute lymphoblastic leukemia, approximately 90% of patients achieve complete remission. However, up to half of patients have persistent minimal/measurable residual disease (MRD) not recognized by routine microscopy, which constitutes the leading de...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou Dalle, Iman, Jabbour, Elias, Short, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065280/
https://www.ncbi.nlm.nih.gov/pubmed/32215194
http://dx.doi.org/10.1177/2040620720910023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065280/
https://www.ncbi.nlm.nih.gov/pubmed/32215194
http://dx.doi.org/10.1177/2040620720910023

Ejemplares similares